Atugen deal with Boehringer Ingelheim

Atugen (Berlin, Germany) will develop GeneBloc reagents to inhibit the expression of target genes provided by Boehringer Ingelheim (Ingelheim, Germany). Atugen also will provide delivery optimization ...